The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels.

Autor: Sanson C; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Boukaiba R; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Houtmann S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Maizières MA; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Fouconnier S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Partiseti M; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France., Bohme GA; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, 13 quai Jules Guesde, F-94403, Vitry-sur-Seine, France. andrees.bohme@sanofi.com.

Publikováno v: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2022 Jun; Vol. 395 (6), pp. 735-740. Date of Electronic Publication: 2022 Apr 12.

Fluorescent- and tagged-protoxin II peptides: potent markers of the Na v 1.7 channel pain target.

Autor: Montnach J; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., De Waard S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Nicolas S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Burel S; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., Osorio N; Laboratory of Cognitive Neuroscience, UMR 7291, CNRS, Aix-Marseille University, Marseille, France., Zoukimian C; Smartox Biotechnology, Saint-Egrève, France., Mantegazza M; Université Cote d'Azur, CNRS UMR 7275, Institute of Molecular and Cellular Pharmacology, Valbonne-Sophia Antipolis, France., Boukaiba R; Sanofi R&D, Integrated Drug Discovery - High Content Biology, Vitry-sur-Seine, France., Béroud R; Smartox Biotechnology, Saint-Egrève, France., Partiseti M; Sanofi R&D, Integrated Drug Discovery - High Content Biology, Vitry-sur-Seine, France., Delmas P; Laboratory of Cognitive Neuroscience, UMR 7291, CNRS, Aix-Marseille University, Marseille, France., Marionneau C; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France., De Waard M; LabEx 'Ion Channels, Science & Therapeutics', l'institut du thorax, INSERM, CNRS, UNIV NANTES, Nantes, France.; Smartox Biotechnology, Saint-Egrève, France.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2021 Jul; Vol. 178 (13), pp. 2632-2650. Date of Electronic Publication: 2021 May 14.

Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse.

Autor: Ledein L; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France., Léger B; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France., Dees C; Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany., Beyer C; Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany., Distler A; Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany., Vettori S; Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy., Boukaiba R; IDD Department, Sanofi, Vitry-sur-Seine, France., Bidouard JP; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France., Schaefer M; R&D Diabetes Division, Sanofi, Frankfurt, Germany., Pernerstorfer J; R&D Diabetes Division, Sanofi, Frankfurt, Germany., Ruetten H; R&D Diabetes Division, Sanofi, Frankfurt, Germany., Jagerschmidt A; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France., Janiak P; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France., Distler JHW; Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany., Distler O; Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland., Illiano S; Cardiovascular & Metabolism Unit, Sanofi, Chilly-Mazarin, France.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2020 Sep; Vol. 177 (18), pp. 4296-4309. Date of Electronic Publication: 2020 Aug 05.

From identification to functional characterization of cyriotoxin-1a, an antinociceptive toxin from the spider Cyriopagopus schioedtei.

Autor: Gonçalves TC; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France.; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France., Benoit E; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France.; Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-Saclay, Gif-sur-Yvette, France., Kurz M; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Lucarain L; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Fouconnier S; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Combemale S; Smartox Biotechnology, Saint-Egrève, France., Jaquillard L; Smartox Biotechnology, Saint-Egrève, France., Schombert B; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Chambard JM; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Boukaiba R; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Hessler G; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Bohme A; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Bialy L; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Hourcade S; Neuroscience Therapeutic Area, Neurodegeneration Research, Sanofi R&D, Chilly-Mazarin, France., Béroud R; Smartox Biotechnology, Saint-Egrève, France., De Waard M; Smartox Biotechnology, Saint-Egrève, France.; Institut du Thorax, Inserm UMR 1087/CNRS UMR 6291, LabEx 'Ion Channels, Science and Therapeutics', Nantes, France., Servent D; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France., Partiseti M; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2019 May; Vol. 176 (9), pp. 1298-1314. Date of Electronic Publication: 2019 Apr 09.

Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Autor: Laface, Carmelo¹ (AUTHOR) carmelo.laface@irccsdebellis.it, Ricci, Angela Dalia¹ (AUTHOR), Vallarelli, Simona¹ (AUTHOR), Ostuni, Carmela¹ (AUTHOR), Rizzo, Alessandro² (AUTHOR), Ambrogio, Francesca³ (AUTHOR), Centonze, Matteo⁴ (AUTHOR) matteo.centonze@irccsdebellis.it, Schirizzi, Annalisa⁵ (AUTHOR) annalisa.schirizzi@irccsdebellis.it, De Leonardis, Giampiero⁵ (AUTHOR) giampiero.deleonardis@irccsdebellis.it, D'Alessandro, Rosalba⁵ (AUTHOR), Lotesoriere, Claudio¹ (AUTHOR) carmelo.laface@irccsdebellis.it, Giannelli, Gianluigi⁶ (AUTHOR)

Publikováno v: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7737. 26p.